Edgewise Therapeutics, Inc. (EWTX) research
Edgewise Therapeutics, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $44.51
- As of
Edgewise Therapeutics, Inc. (EWTX): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-06.
As of . Source: SEC EDGAR filings for EWTX. Method and limitations.
Share the EWTX intelligence card
See EWTX live in the terminal
Track EWTX's insider trades, 13F flows, options positioning, and cross asset confluence as they update, on one live board. Free account.
Open the live EWTX terminal, freeActive signals for EWTX
- highCONSENSUS_BUY
3 tracked funds increased EWTX this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +703% to EWTX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +109% to EWTX (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 80% of EWTX (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +1659% to EWTX (2026Q2)
FREE, NO ACCOUNT
Every signal on EWTX, as it fires
You are seeing 5 of 25 signals recorded on EWTX since 2026-05-16.
The five above landed across 2 days. The other 20 were recorded on 4 other days. 20 of the 25 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in EWTX (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 28036F105 · 2026Q2 | $19.1M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 28036F105 · 2026Q2 | $7.7M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 28036F105 · 2026Q2 | $4.8M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 28036F105 · 2026Q2 | $2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, EWTX
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
EWTX against its peers
EWTX's return on equity of -32.1% ranks in the 41st percentile of 22 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | EWTX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 264M | n/a | 17 |
| Operating margin | n/a | -72.8% | n/a | 17 |
| Net margin | n/a | -52.0% | n/a | 17 |
| Return on equity | -32.1% | -26.0% | 41 | 22 |
Peers (24): ACAD, DFTX, IOVA, MANE, TLX, ERAS, APLS, DNTH, RLAY, CRSP, XENE, PTCT, TNGX, LGND, CELC, COGT, ELVN, CPRX, TVTX, ORKA, IDYA, GRAL, CNTA, MIRM. Left out: PBLS (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (EWTX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more EWTX signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to EWTXand get the insider, 13F, options, and confluence read in one view.